NYSE:DGX

Quest Diagnostics Stock Forecast, Price & News

$133.69
+3.67 (+2.82 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$128.33
Now: $133.69
$133.90
50-Day Range
$116.87
MA: $125.71
$131.09
52-Week Range
$98.89
Now: $133.69
$134.71
Volume2.12 million shs
Average Volume1.33 million shs
Market Capitalization$17.54 billion
P/E Ratio16.53
Dividend Yield1.91%
Beta1.07
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Quest Diagnostics logo

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
CUSIP74834L10
Phone973-520-2700
Employees40,000
Year Founded1967

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.73 billion
Cash Flow$9.69 per share
Book Value$42.22 per share

Profitability

Net Income$858 million

Miscellaneous

Market Cap$17.54 billion
Next Earnings DateN/A
OptionableOptionable

Headlines

Quest Diagnostics (NYSE:DGX) Issues Earnings Results
April 22, 2021 |  americanbankingnews.com
Quest Diagnostics Lifts HY Outlook
April 22, 2021 |  markets.businessinsider.com
DGX October 15th Options Begin Trading
April 12, 2021 |  nasdaq.com
Ex-Dividend Date Insight: Quest Diagnostics
April 5, 2021 |  benzinga.com
See More Headlines

MarketRank

Overall MarketRank

1.91 out of 5 stars

Medical Sector

93rd out of 2,024 stocks

Medical Laboratories Industry

1st out of 39 stocks

Analyst Opinion: 1.2Community Rank: 1.7Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
$133.69
+3.67 (+2.82 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

Is Quest Diagnostics a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 9 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Quest Diagnostics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DGX, but not buy additional shares or sell existing shares.
View analyst ratings for Quest Diagnostics
or view top-rated stocks.

What stocks does MarketBeat like better than Quest Diagnostics?

Wall Street analysts have given Quest Diagnostics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Quest Diagnostics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Incorporated (NYSE:DGX) announced its quarterly earnings results on Thursday, April, 22nd. The medical research company reported $3.76 earnings per share for the quarter, hitting the Zacks' consensus estimate of $3.76. The medical research company had revenue of $2.72 billion for the quarter, compared to analysts' expectations of $2.66 billion. Quest Diagnostics had a trailing twelve-month return on equity of 19.23% and a net margin of 13.22%. The firm's revenue was up 49.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.94 EPS.
View Quest Diagnostics' earnings history
.

How has Quest Diagnostics' stock been impacted by COVID-19?

Quest Diagnostics' stock was trading at $99.73 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DGX stock has increased by 34.1% and is now trading at $133.69.
View which stocks have been most impacted by COVID-19
.

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics declared a quarterly dividend on Thursday, February 4th. Shareholders of record on Wednesday, April 7th will be paid a dividend of $0.62 per share on Wednesday, April 21st. This represents a $2.48 annualized dividend and a dividend yield of 1.86%. The ex-dividend date is Tuesday, April 6th. This is an increase from Quest Diagnostics's previous quarterly dividend of $0.56.
View Quest Diagnostics' dividend history
.

Is Quest Diagnostics a good dividend stock?

Quest Diagnostics pays an annual dividend of $2.48 per share and currently has a dividend yield of 1.91%. Quest Diagnostics does not yet have a strock track record of dividend growth. The dividend payout ratio of Quest Diagnostics is 37.80%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 23.29% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.
View Quest Diagnostics' dividend history.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics declared that its board has authorized a share buyback plan on Thursday, February 4th 2021, which authorizes the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 6.1% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's board believes its stock is undervalued.

What price target have analysts set for DGX?

15 Wall Street analysts have issued 12-month price targets for Quest Diagnostics' stock. Their forecasts range from $99.00 to $158.00. On average, they anticipate Quest Diagnostics' share price to reach $130.40 in the next twelve months. This suggests that the stock has a possible downside of 2.5%.
View analysts' price targets for Quest Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the following people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 64, Pay $2.73M)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 59) (LinkedIn Profile)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 58, Pay $1.03M)
  • Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 46, Pay $976.36k)
  • Mr. Michael J. Deppe, VP, Corp. Controller & Chief Accounting Officer (Age 54)
  • Ms. Gabrielle Wolfson, Sr. VP and Chief Information & Digital Officer (LinkedIn Profile)
  • Mr. Shawn C. Bevec, VP of Investor Relation (LinkedIn Profile)
  • Mr. Michael E. Prevoznik, Sr. VP & Gen. Counsel (Age 59) (LinkedIn Profile)
  • Mr. Timothy Sharpe, VP of Compliance
  • Mr. Gary D. Samuels, VP of Corp. Communications

What is Steve Rusckowski's approval rating as Quest Diagnostics' CEO?

1,053 employees have rated Quest Diagnostics CEO Steve Rusckowski on Glassdoor.com. Steve Rusckowski has an approval rating of 78% among Quest Diagnostics' employees.

Who are some of Quest Diagnostics' key competitors?

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), Abbott Laboratories (ABT), NVIDIA (NVDA), Intel (INTC) and Cisco Systems (CSCO).

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by a number of retail and institutional investors. Top institutional investors include Scharf Investments LLC (0.49%), Wedge Capital Management L L P NC (0.19%), Retirement Systems of Alabama (0.16%), New York State Teachers Retirement System (0.12%), Coho Partners Ltd. (0.11%) and Galvin Gaustad & Stein LLC (0.09%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Daniel Stanzione, Gail R Wilensky, J E Davis, Manner Carrie Eglinton, Mark Guinan, Michael E Prevoznik, Michael J Deppe and Stephen H Rusckowski.
View institutional ownership trends for Quest Diagnostics
.

Which major investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including DnB Asset Management AS, Coho Partners Ltd., John G Ullman & Associates Inc., Chevy Chase Trust Holdings Inc., New York State Teachers Retirement System, Sentry Investment Management LLC, BOKF NA, and Crossmark Global Holdings Inc.. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Daniel Stanzione, Manner Carrie Eglinton, Mark Guinan, Michael E Prevoznik, Michael J Deppe, and Stephen H Rusckowski.
View insider buying and selling activity for Quest Diagnostics
or view top insider-selling stocks.

Which major investors are buying Quest Diagnostics stock?

DGX stock was bought by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, Hennessy Advisors Inc., First Citizens Bank & Trust Co., Bowling Portfolio Management LLC, Members Capital Advisors Inc., Pacer Advisors Inc., MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH, and Hallmark Capital Management Inc..
View insider buying and selling activity for Quest Diagnostics
or or view top insider-buying stocks.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $133.69.

How much money does Quest Diagnostics make?

Quest Diagnostics has a market capitalization of $17.54 billion and generates $7.73 billion in revenue each year. The medical research company earns $858 million in net income (profit) each year or $6.56 on an earnings per share basis.

How many employees does Quest Diagnostics have?

Quest Diagnostics employs 40,000 workers across the globe.

Does Quest Diagnostics have any subsidiaries?

The following companies are subsidiares of Quest Diagnostics: AmeriPath, AmeriPath Cincinnati Inc. (OH), AmeriPath Cleveland Inc. (OH), AmeriPath Consolidated Labs Inc. (FL), AmeriPath Florida LLC (DE), AmeriPath Hospital Services Florida LLC (DE), AmeriPath Inc. (DE), AmeriPath Indianapolis PC (IN), AmeriPath Kentucky Inc. (KY), AmeriPath Lubbock 5.01(A) Corporation (TX), AmeriPath New York LLC (DE), AmeriPath Texas Inc. (DE), AmeriPath Tucson Inc. (AZ), American Medical Laboratories, American Medical Laboratories Incorporated (DE), Associated Clinical Laboratories L.P. (PA), Associated Clinical Laboratories of Pennsylvania L.L.C. (PA), Athena Diagnostics, Athena Diagnostics Inc. (DE), Blueprint Genetics, Blueprint Genetics FZ-LLC (UAE), Blueprint Genetics Inc. (DE), Blueprint Genetics Oy (Finland), California Laboratory Associates, Cape Cod Healthcare - Business, Celera, ClearPoint Diagnostic, Clearpoint Diagnostic Laboratories LLC (TX), Cleveland HeartLab, Cleveland HeartLab Inc. (DE), Clinical Laboratory Partners, Colorado Pathology Consultants P.C. (CO), ConVerge Diagnostic Services, Consolidated DermPath Inc. (DE), DFW 5.01(a) Corporation (TX), DGXWMT JV LLC (DE), Dermatopathology of Wisconsin S.C. (WI), Diagnostic Laboratory of Oklahoma LLC (OK), Diagnostic Pathology Services Inc. (OK), Diagnostic Reference Services Inc. (MD), ExamOne Canada Inc. (New Brunswick), ExamOne LLC (DE), ExamOne World Wide Inc. (PA), ExamOne World Wide of NJ Inc. (NJ), Focus Diagnostics, HemoCue, Hoffman M.D. Associated Pathologists Chartered (NV), Institute for Dermatopathology Inc. (PA), Isabella Street Urban Renewal LLC (NJ), Kailash B. Sharma M.D. Inc. (GA), Kilpatrick Pathology P.A. (NC), LabOne, LabOne LLC (MO), LabOne of Ohio Inc. (DE), Laboratorio de Analisis Biomedicos S.A. (Mexico), Lancet Labs, MACL, Med Fusion LLC (TX), Med fusion, MedPlus, Mid America Clinical Laboratories LLC (IN), Nomad Massachusetts Inc. (MA), Nuclear Medicine and Pathology Associates (GA), Ocmulgee Medical Pathology Association Inc. (GA), Pathology Building Partnership (MD) (gen. ptnrshp.), PeaceHealth Laboratories, PhenoPath Laboratories, PhenoPath Laboratories PLLC (WA), Q Squared Solutions Holdings LLC (DE), Q Squared Solutions Holdings Limited (UK), Quest Diagnostics (Shanghai) Co. Ltd. (China), Quest Diagnostics Brasil Holdings Ltd. (UK), Quest Diagnostics Clinical Laboratories, Quest Diagnostics Clinical Laboratories Inc. (DE), Quest Diagnostics Domestic Holder LLC (DE), Quest Diagnostics HTAS India Private Limited (India), Quest Diagnostics Health & Wellness LLC (DE), Quest Diagnostics Holdings Incorporated (DE), Quest Diagnostics Holdings Ltd. (UK), Quest Diagnostics Incorporated (MD), Quest Diagnostics Incorporated (NV), Quest Diagnostics India Private Limited (India), Quest Diagnostics Infectious Disease Inc. (DE), Quest Diagnostics International Holdings Limited (UK), Quest Diagnostics International LLC (DE), Quest Diagnostics Investments LLC (DE), Quest Diagnostics Ireland Limited (Ireland), Quest Diagnostics LLC (CT), Quest Diagnostics LLC (IL), Quest Diagnostics LLC (MA), Quest Diagnostics Massachusetts LLC (MA), Quest Diagnostics Mexico Holding Company Trust (Mexico), Quest Diagnostics Mexico S de RL de CV (Mexico), Quest Diagnostics Nichols Institute (CA), Quest Diagnostics Nichols Institute Inc. (VA), Quest Diagnostics Receivables Inc. (DE), Quest Diagnostics Subsidiary Holdings Ltd. (UK), Quest Diagnostics TB LLC (DE), Quest Diagnostics Terracotta LLC (DE), Quest Diagnostics Venture LLC (PA), Quest Diagnostics Ventures LLC (DE), Quest Diagnostics do Brasil Ltda. (Brazil), Quest Diagnostics of Pennsylvania Inc. (DE), Quest Diagnostics of Puerto Rico Inc. (PR), Quest HealthConnect LLC (CA), ReproSource, Reprosource Fertility Diagnostics Inc. (MA), Solstas Lab Partners, Sonora Quest Laboratories LLC (AZ), Specialty Laboratories Inc. (CA), Summit Health, UMass Memorial Medical Center - Anatomic Pathology Outreach Laboratory Business, Unilab Corporation, and Unilab Corporation (DE).

When was Quest Diagnostics founded?

Quest Diagnostics was founded in 1967.

What is Quest Diagnostics' official website?

The official website for Quest Diagnostics is www.questdiagnostics.com.

Where are Quest Diagnostics' headquarters?

Quest Diagnostics is headquartered at 500 PLAZA DRIVE, SECAUCUS NJ, 07094.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected]


This page was last updated on 4/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.